Acuvi (ACUVI) Q4 2025 earnings summary

Executive summary

• Net sales reached SEK 204 million in 2025, up 16%–18% from SEK 176 million, driven by key customer projects and a shift to direct sales channels.

• Q4 net sales grew by 25% to SEK 54 million, with growth fueled by deeper customer relationships and transitioning from distributors to in-house sales.

• Adjusted EBITDA for the year was SEK 33 million (16% margin), while reported EBITDA was SEK 20 million (10% margin), impacted by non-recurring costs.

• Strategic milestones included a new CEO, expansion in Japan, and a focus on high-margin products and direct customer relationships.

Financial highlights

• Full-year net sales increased to SEK 204 million, with Q4 net sales at SEK 54 million, up 25% year-over-year.

• Q4 EBITDA was negative SEK 6 million (margin -11%), but adjusted EBITDA was positive SEK 2 million after SEK 13 million in adjustments.

• Net income for 2025 was -15.3 MSEK, with earnings per share at -0.47 SEK.

• Cash and cash equivalents at year-end were 16.6 MSEK, up from 12.7 MSEK the previous year.

• Adjustments included costs for closing a Swiss office, ERP implementation errors, acquisition-related costs, a fixed price project, and a license dispute.

Outlook and guidance

• 2026 EBITDA target is SEK 37–50 million, with top-line growth of at least 10% and focus on high-margin products and new markets.

• Market demand remains robust in precision motion for medtech, lab automation, and semiconductors.

• Focus remains on optimizing product mix and expanding into new markets such as space and energy.